Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis

PURPOSE: To report on a case of uveitis and scleritis resulting as an immune-mediated side effect of cancer immunotherapy with nivolumab and cabiralizumab. OBSERVATIONS: Bilateral anterior nongranulomatous anterior uveitis and bilateral diffuse anterior and posterior scleritis occurred following the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzales, John A., Shantha, Jessica, Acharya, Nisha R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Brief report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834645/
https://www.ncbi.nlm.nih.gov/pubmed/29511745
http://dx.doi.org/10.1016/j.ajoc.2018.02.005
Descripción
Sumario:PURPOSE: To report on a case of uveitis and scleritis resulting as an immune-mediated side effect of cancer immunotherapy with nivolumab and cabiralizumab. OBSERVATIONS: Bilateral anterior nongranulomatous anterior uveitis and bilateral diffuse anterior and posterior scleritis occurred following the use of combination cancer immunotherapy. The uveitis and scleritis resolved following temporary discontinuation of nivolumab and cabiralizumab as well as systemic prednisone. CONCLUSIONS AND IMPORTANCE: Ophthalmologists should be aware of the possibility of acute ocular inflammation developing with cancer immunotherapy. Systemic corticosteroids play a first-line role in managing such immune-mediated side effects.

Ejemplares similares